JP2023162343A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023162343A5 JP2023162343A5 JP2023139455A JP2023139455A JP2023162343A5 JP 2023162343 A5 JP2023162343 A5 JP 2023162343A5 JP 2023139455 A JP2023139455 A JP 2023139455A JP 2023139455 A JP2023139455 A JP 2023139455A JP 2023162343 A5 JP2023162343 A5 JP 2023162343A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- antigen
- binding fragment
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 54
- 239000000427 antigen Substances 0.000 claims 28
- 102000036639 antigens Human genes 0.000 claims 28
- 108091007433 antigens Proteins 0.000 claims 28
- 239000012634 fragment Substances 0.000 claims 28
- 238000012423 maintenance Methods 0.000 claims 28
- 102000010787 Interleukin-4 Receptors Human genes 0.000 claims 12
- 108010038486 Interleukin-4 Receptors Proteins 0.000 claims 12
- 229950003468 dupilumab Drugs 0.000 claims 10
- 229940125369 inhaled corticosteroids Drugs 0.000 claims 10
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 239000000048 adrenergic agonist Substances 0.000 claims 6
- 208000006673 asthma Diseases 0.000 claims 6
- 230000001419 dependent effect Effects 0.000 claims 6
- 230000002327 eosinophilic effect Effects 0.000 claims 6
- 229940124624 oral corticosteroid Drugs 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 229940090047 auto-injector Drugs 0.000 claims 4
- 238000011418 maintenance treatment Methods 0.000 claims 4
- 239000003246 corticosteroid Substances 0.000 claims 2
- 238000010254 subcutaneous injection Methods 0.000 claims 2
- 239000007929 subcutaneous injection Substances 0.000 claims 2
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025020415A JP2025072593A (ja) | 2014-02-21 | 2025-02-12 | Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法 |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461943019P | 2014-02-21 | 2014-02-21 | |
| US61/943,019 | 2014-02-21 | ||
| EP14306413 | 2014-09-15 | ||
| EP14306413.7 | 2014-09-15 | ||
| US201462077669P | 2014-11-10 | 2014-11-10 | |
| US62/077,669 | 2014-11-10 | ||
| JP2020036331A JP6893265B2 (ja) | 2014-02-21 | 2020-03-04 | Ｉｌ−４ｒ拮抗薬の投与により喘息を処置または予防するための方法 |
| JP2021089717A JP7343547B2 (ja) | 2014-02-21 | 2021-05-28 | Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021089717A Division JP7343547B2 (ja) | 2014-02-21 | 2021-05-28 | Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025020415A Division JP2025072593A (ja) | 2014-02-21 | 2025-02-12 | Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023162343A JP2023162343A (ja) | 2023-11-08 |
| JP2023162343A5 true JP2023162343A5 (enExample) | 2024-07-25 |
| JP7636487B2 JP7636487B2 (ja) | 2025-02-26 |
Family
ID=51570453
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016552595A Active JP6673840B2 (ja) | 2014-02-21 | 2015-02-20 | Ｉｌ−４ｒ拮抗薬の投与により喘息を処置または予防するための方法 |
| JP2023139455A Active JP7636487B2 (ja) | 2014-02-21 | 2023-08-30 | Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法 |
| JP2025020415A Pending JP2025072593A (ja) | 2014-02-21 | 2025-02-12 | Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016552595A Active JP6673840B2 (ja) | 2014-02-21 | 2015-02-20 | Ｉｌ−４ｒ拮抗薬の投与により喘息を処置または予防するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025020415A Pending JP2025072593A (ja) | 2014-02-21 | 2025-02-12 | Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10137193B2 (enExample) |
| EP (3) | EP4382164A3 (enExample) |
| JP (3) | JP6673840B2 (enExample) |
| KR (4) | KR20220029765A (enExample) |
| CN (1) | CN106232140A (enExample) |
| AU (3) | AU2015218808B2 (enExample) |
| CA (1) | CA2940295A1 (enExample) |
| ES (2) | ES2897631T3 (enExample) |
| HU (1) | HUE065844T2 (enExample) |
| IL (1) | IL315136A (enExample) |
| MX (2) | MX384192B (enExample) |
| PL (2) | PL3107575T3 (enExample) |
| PT (2) | PT3107575T (enExample) |
| RU (1) | RU2713406C2 (enExample) |
| WO (1) | WO2015127229A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| JP6306588B2 (ja) | 2012-08-21 | 2018-04-04 | サノフィ・バイオテクノロジー | Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法 |
| TWI755763B (zh) | 2013-06-04 | 2022-02-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
| EP3010539B1 (en) | 2013-06-21 | 2019-07-24 | Sanofi Biotechnology | Methods for treating nasal polyposis by administering an il-4r antagonist |
| TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| SMT202100119T1 (it) | 2013-07-12 | 2021-05-07 | Knopp Biosciences Llc | Trattamento dei livelli elevati di eosinofili e/o basofili |
| IL315136A (en) * | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4rantagonist |
| EP3110848B1 (en) | 2014-02-28 | 2024-02-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating skin infection by administering an il-4r antagonist |
| JP6861630B2 (ja) | 2014-11-14 | 2021-04-21 | サノフィ・バイオテクノロジー | Ｉｌ−４ｒアンタゴニストの投与により鼻ポリープを伴う慢性副鼻腔炎を処置する方法 |
| US20180056018A1 (en) * | 2016-08-31 | 2018-03-01 | Cephalon, Inc. | Inhalation Systems, Devices and Methods |
| CN118141914A (zh) * | 2016-09-01 | 2024-06-07 | 瑞泽恩制药公司 | 用于通过施用il-4r拮抗剂来预防或治疗变态反应的方法 |
| KR20190053250A (ko) | 2016-09-22 | 2019-05-17 | 리제너론 파아마슈티컬스, 인크. | Il-4r 저해제 투여에 의한 중증 아토피 피부염의 치료 방법 |
| US10485844B2 (en) | 2016-09-22 | 2019-11-26 | Regeneron Pharmaceuticals, Inc. | Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor |
| TWI857389B (zh) * | 2016-12-01 | 2024-10-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| EP3957752B1 (en) | 2017-04-13 | 2025-08-20 | Regeneron Pharmaceuticals, Inc. | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1 |
| WO2019005898A1 (en) | 2017-06-27 | 2019-01-03 | Ohio State Innovation Foundation | LIPONUCLEOTID THERAPY FOR COPD |
| EP3645010A4 (en) * | 2017-06-27 | 2021-03-24 | Ohio State Innovation Foundation | NUCLEOTIDE-BASED THERAPY FOR ASTHMA |
| US11053309B2 (en) | 2017-08-04 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating active eosinophilic esophagitis |
| EP4344706A3 (en) * | 2017-10-30 | 2024-05-22 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4r antagonist |
| MA52624A (fr) | 2018-05-13 | 2021-03-24 | Regeneron Pharma | Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4r |
| TWI838388B (zh) * | 2018-07-10 | 2024-04-11 | 美商雷傑納榮製藥公司 | 修飾結合分子以最小化已存在的交互作用 |
| CN110872349A (zh) | 2018-09-04 | 2020-03-10 | 三生国健药业（上海）股份有限公司 | 结合人il-4r的抗体、其制备方法和用途 |
| CN110746507B (zh) | 2018-12-25 | 2020-06-26 | 江苏荃信生物医药有限公司 | 抗人白介素4受体α单克隆抗体及其应用 |
| MY209489A (en) * | 2018-12-27 | 2025-07-12 | Akeso Biopharma Inc | Antibody against human il-4ra and use thereof |
| WO2020191346A1 (en) | 2019-03-21 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
| EP3962515A1 (en) * | 2019-05-01 | 2022-03-09 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-33 antagonist |
| EP3999114A1 (en) * | 2019-07-16 | 2022-05-25 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4r antagonist |
| SG11202113310UA (en) | 2019-08-05 | 2021-12-30 | Regeneron Pharma | Methods for treating atopic dermatitis by administering an il-4r antagonist |
| EP4010001A1 (en) | 2019-08-05 | 2022-06-15 | Regeneron Pharmaceuticals, Inc. | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist |
| EP3992974A1 (en) | 2020-11-02 | 2022-05-04 | Sanofi Biotechnology | Methods for treating digitally-identified il-4/il-13 related disorders |
| AU2020399975A1 (en) * | 2019-12-09 | 2022-07-28 | Sanofi Biotechnology | Methods for treating digitally-identified IL-4/IL-13 related disorders |
| MX2023001140A (es) * | 2020-08-05 | 2023-05-18 | Areteia Therapeutics Inc | Uso del dexpramipexol para el tratamiento de asma moderado a grave. |
| US20220169739A1 (en) * | 2020-10-05 | 2022-06-02 | Sanofi Biotechnology | Methods for treating asthma in pediatric subjects by administering an il-4r antagonist |
| TW202313692A (zh) * | 2021-08-26 | 2023-04-01 | 大陸商正大天晴藥業集團股份有限公司 | 抗ｉｌ４ｒ抗體的藥物組成物及其用途 |
| CN117368487A (zh) * | 2023-09-28 | 2024-01-09 | 首都医科大学附属北京同仁医院 | 一种利用局部IgE预测或评估奥马珠单抗在治疗复发性鼻息肉中疗效的方法和应用 |
| US20250230251A1 (en) | 2023-12-20 | 2025-07-17 | Bristol-Myers Squibb Company | Antibodies targeting il-18 receptor beta (il-18rb) and related methods |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8808015D0 (en) | 1988-04-06 | 1988-05-05 | Ritter M A | Chemical compounds |
| AU643427B2 (en) | 1988-10-31 | 1993-11-18 | Immunex Corporation | Interleukin-4 receptors |
| US5714146A (en) | 1992-08-26 | 1998-02-03 | Board Of Regents Of The University Of Washington | IL-4 bone therapy |
| EP0604693A1 (en) | 1992-12-29 | 1994-07-06 | Schering-Plough | Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same |
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| MXPA02011682A (es) | 2000-05-26 | 2003-05-14 | Immunex Corp | Uso de antagonistas de interleuquina-4 y composiciones de los mismos. |
| US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US8178098B2 (en) | 2001-04-03 | 2012-05-15 | National Jewish Health | Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies |
| WO2005047331A2 (en) | 2003-11-07 | 2005-05-26 | Immunex Corporation | Antibodies that bind interleukin-4 receptor |
| AU2004309373A1 (en) | 2003-12-22 | 2005-07-14 | Amgen Inc. | Methods for identifying functional antibodies |
| ATE395358T1 (de) | 2004-02-27 | 2008-05-15 | Regeneron Pharma | Il-4/il-13-spezifische polypetide und deren therapeutische verwendung |
| US20090098142A1 (en) | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
| TW200902555A (en) | 2005-01-03 | 2009-01-16 | Hoffmann La Roche | Antibodies against IL-13 receptor alpha 1 and uses thereof |
| BRPI0710572A2 (pt) * | 2006-01-24 | 2013-01-08 | Domantis Ltd | ligante, uso do ligante, mÉtodos para o tratamento de uma doenÇa alÉrgica, de asma e de cÂncer, para a inibiÇço de uma resposta imune do tipo th2, e administraÇço de tratamento anti-il-4 e tratamento anti-il-13, composiÇço farmacÊutica, dispositivo de dispensaÇço de droga, Ácido nucleico isolado ou recombinante, vetor, cÉlula hospedeira, mÉtodos para a produÇço de um ligante e de inibiÇço da proliferaÇço de cÉlulas |
| PL2374818T3 (pl) | 2006-06-02 | 2013-05-31 | Regeneron Pharma | Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6 |
| PL2069403T3 (pl) | 2006-10-02 | 2015-08-31 | Regeneron Pharma | Przeciwciała ludzkie o wysokim powinowactwie wobec receptora ludzkiej IL-4 |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| EP2022507A1 (en) | 2007-08-07 | 2009-02-11 | Universität Hamburg | Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy |
| EP2050764A1 (en) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| EP2245064B1 (en) * | 2007-12-21 | 2014-07-23 | Medimmune Limited | BINDING MEMBERS FOR INTERLEUKIN-4 RECEPTOR ALPHA (IL-4Ralpha) |
| US20120004205A1 (en) | 2008-12-01 | 2012-01-05 | Cincinnati Children's Hospital Medical Center | Il-13 induced gene signature for eosinophilic esophagitis |
| WO2010120524A2 (en) | 2009-03-31 | 2010-10-21 | Altair Therapeutics, Inc. | Methods of modulating an immune response to a viral infection |
| WO2011156000A2 (en) * | 2010-06-07 | 2011-12-15 | Aerovance, Inc. | Use of il-4/il-13 antagonists to treat eosinophilic disorders |
| AU2011312191B2 (en) | 2010-10-06 | 2015-07-02 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies |
| HUE034005T2 (en) * | 2010-10-15 | 2018-01-29 | Medimmune Ltd | Therapies for improving lung function |
| US20130052190A1 (en) | 2011-02-22 | 2013-02-28 | Oxagen Limited | CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions |
| WO2013066780A2 (en) * | 2011-11-01 | 2013-05-10 | Medimmune, Llc | Methods for reducing the frequency and severity of acute exacerbations of asthma |
| JP6306588B2 (ja) | 2012-08-21 | 2018-04-04 | サノフィ・バイオテクノロジー | Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法 |
| ES2981062T3 (es) | 2012-09-07 | 2024-10-07 | Regeneron Pharma | Métodos para el tratamiento de la dermatitis atópica administrando un antagonista de IL-4R |
| EP3010539B1 (en) | 2013-06-21 | 2019-07-24 | Sanofi Biotechnology | Methods for treating nasal polyposis by administering an il-4r antagonist |
| IL315136A (en) | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4rantagonist |
| JP6861630B2 (ja) | 2014-11-14 | 2021-04-21 | サノフィ・バイオテクノロジー | Ｉｌ−４ｒアンタゴニストの投与により鼻ポリープを伴う慢性副鼻腔炎を処置する方法 |
| EP4344706A3 (en) * | 2017-10-30 | 2024-05-22 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4r antagonist |
| US20220169739A1 (en) | 2020-10-05 | 2022-06-02 | Sanofi Biotechnology | Methods for treating asthma in pediatric subjects by administering an il-4r antagonist |
-
2015
- 2015-02-19 IL IL315136A patent/IL315136A/en unknown
- 2015-02-20 PL PL15708991T patent/PL3107575T3/pl unknown
- 2015-02-20 MX MX2016010854A patent/MX384192B/es unknown
- 2015-02-20 PL PL21191120.1T patent/PL3973987T3/pl unknown
- 2015-02-20 CA CA2940295A patent/CA2940295A1/en active Pending
- 2015-02-20 EP EP24150594.0A patent/EP4382164A3/en active Pending
- 2015-02-20 KR KR1020227006120A patent/KR20220029765A/ko not_active Ceased
- 2015-02-20 US US14/627,728 patent/US10137193B2/en active Active
- 2015-02-20 EP EP21191120.1A patent/EP3973987B1/en active Active
- 2015-02-20 KR KR1020167025669A patent/KR102368450B1/ko active Active
- 2015-02-20 ES ES15708991T patent/ES2897631T3/es active Active
- 2015-02-20 RU RU2016136364A patent/RU2713406C2/ru active
- 2015-02-20 KR KR1020257035292A patent/KR20250154567A/ko active Pending
- 2015-02-20 JP JP2016552595A patent/JP6673840B2/ja active Active
- 2015-02-20 CN CN201580020533.9A patent/CN106232140A/zh active Pending
- 2015-02-20 PT PT157089913T patent/PT3107575T/pt unknown
- 2015-02-20 KR KR1020237041236A patent/KR20230167770A/ko not_active Ceased
- 2015-02-20 EP EP15708991.3A patent/EP3107575B1/en active Active
- 2015-02-20 HU HUE21191120A patent/HUE065844T2/hu unknown
- 2015-02-20 AU AU2015218808A patent/AU2015218808B2/en active Active
- 2015-02-20 PT PT211911201T patent/PT3973987T/pt unknown
- 2015-02-20 ES ES21191120T patent/ES2977332T3/es active Active
- 2015-02-20 WO PCT/US2015/016852 patent/WO2015127229A1/en not_active Ceased
-
2016
- 2016-08-19 MX MX2021008113A patent/MX2021008113A/es unknown
-
2018
- 2018-10-11 US US16/157,708 patent/US20190125865A1/en not_active Abandoned
-
2020
- 2020-11-26 AU AU2020277191A patent/AU2020277191B2/en active Active
-
2021
- 2021-03-29 US US17/215,604 patent/US20210322546A1/en active Pending
-
2023
- 2023-08-30 JP JP2023139455A patent/JP7636487B2/ja active Active
-
2024
- 2024-06-06 AU AU2024203849A patent/AU2024203849A1/en active Pending
-
2025
- 2025-02-12 JP JP2025020415A patent/JP2025072593A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023162343A5 (enExample) | ||
| JP2025072593A5 (enExample) | ||
| JP2017507139A5 (enExample) | ||
| JP2023139071A5 (enExample) | ||
| JP2023103389A (ja) | Ｉｌ－４ｒ阻害剤の投与によるアレルギー処置方法およびアレルゲン特異的免疫療法の向上方法 | |
| RU2016136364A (ru) | Способы лечения или предупреждения астмы посредством введения антагониста il-4r | |
| US6623736B2 (en) | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders | |
| CN104755495A (zh) | 通过施用il-4r拮抗剂治疗或预防哮喘的方法 | |
| US20010026801A1 (en) | Cytokine antagonists for the treatment of localized disorders | |
| JP2022160685A5 (enExample) | ||
| RU2015114923A (ru) | СПОСОБЫ ЛЕЧЕНИЯ IL-1β-ЗАВИСИМЫХ ЗАБОЛЕВАНИЙ | |
| CA2918105C (en) | Methods for reducing exacerbation rates of asthma using benralizumab | |
| JP2009541374A5 (enExample) | ||
| CN102884081A (zh) | 用dll4拮抗剂治疗自身免疫疾病的方法 | |
| RU2014101207A (ru) | Новые показания к применению при лечении антителами против il-1-бета | |
| RU2014117510A (ru) | Лечение ревматоидного артрита | |
| KR102337599B1 (ko) | 벤랄리주맙을 이용하여 천식 환자에서 강제 호기량을 증가시키는 방법 | |
| JPWO2021026205A5 (enExample) | ||
| JP2020073525A5 (enExample) | ||
| JPWO2020223541A5 (enExample) | ||
| JP2019535716A5 (enExample) | ||
| JP2005529152A5 (enExample) | ||
| CN118355034A (zh) | 施用il-4/il-13拮抗剂以减弱特应性进程的方法 | |
| JPWO2021195530A5 (enExample) | ||
| CA3176673A1 (en) | Pan-elr+ cxc chemokine antibodies for the treatment of respiratory disease |